{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:29:26Z","timestamp":1793640566535,"version":"4.5.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009886","name":"Regione Puglia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP D74C22000040002"],"award-info":[{"award-number":["CUP D74C22000040002"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP D53D23014290006"],"award-info":[{"award-number":["CUP D53D23014290006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-MR1-2023-12377571"],"award-info":[{"award-number":["PNRR-MR1-2023-12377571"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PNRR-M6\/C2"],"award-info":[{"award-number":["PNRR-M6\/C2"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019771","name":"European Union&apos;s Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CUP UNIFG D73C22001230006"],"award-info":[{"award-number":["CUP UNIFG D73C22001230006"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PNRR\\u2014M4C2-I1.3"],"award-info":[{"award-number":["PNRR\\u2014M4C2-I1.3"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministry of Education, University and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016112","name":"University of Foggia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T12:47:01Z","timestamp":1748868421000},"page":"1513-1523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience"],"prefix":"10.1016","volume":"8","author":[{"given":"Giuseppina","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Iole","family":"Natalicchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Garofoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio Di","family":"Tullio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mancino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Masucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Emanuele","family":"Chiuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Fratino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Zanardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Schepisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Brighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cornacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sanguedolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo De","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Landriscina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.05.002_b0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.05.002_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.764758","article-title":"Highlighting the place of metastasis-directed therapy in isolated liver metastases in prostate cancer: a case report","volume":"11","author":"Yeo","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0015","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0020","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormonesensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.05.002_b0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in noncastrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0030","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.05.002_b0040","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2025.05.002_b0045","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.05.002_b0050","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a035568","article-title":"Erratum: metastases in prostate cancer","volume":"8","author":"La Manna","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.euo.2025.05.002_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309941","article-title":"Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients","volume":"19","author":"Lai","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2025.05.002_b0060","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/sj.pcan.4500573","article-title":"Clinical significance of pulmonary metastasis in stage D2 prostate cancer patients","volume":"5","author":"Nakamachi","year":"2002","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2025.05.002_b0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","article-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Pond","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.002_b0070","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0075","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1016\/j.euo.2025.05.002_b0080","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/annonc\/mdx155","article-title":"Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study","volume":"28","author":"Conteduca","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0085","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.05.002_b0090","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00345-024-05341-2","article-title":"Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancer","volume":"42","author":"Wenzel","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.05.002_b0095","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41391-022-00605-7","article-title":"Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry","volume":"26","author":"van den Bergh","year":"2023","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2025.05.002_b0100","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.euf.2016.08.007","article-title":"In men with castration-resistant prostate cancer, visceral metastases predict shorter overall survival: what predicts visceral metastases? Results from the SEARCH database","volume":"3","author":"Whitney","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.05.002_b0105","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2217\/fon.15.158","article-title":"Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients","volume":"11","author":"Conteduca","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/pcan.2013.41","article-title":"Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"17","author":"Goodman","year":"2014","journal-title":"Prostate Cancer Prostat Dis"},{"issue":"Suppl 15","key":"10.1016\/j.euo.2025.05.002_b0115","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1200\/jco.2012.30.15_suppl.4655","article-title":"Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)","volume":"30","author":"Kelly","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.002_b0135","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.05.002_b0140","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.05.002_b0150","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0155","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.05.002_b0160","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.05.002_b0165","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.eururo.2020.12.040","article-title":"The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited","volume":"80","author":"Deek","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.05.002_b0170","article-title":"Genomic features of lung-recurrent hormone-sensitive prostate cancer","volume":"6","author":"Fonseca","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2025.05.002_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306525","article-title":"Comprehensive transcriptomic analysis of prostate cancer lung metastases","volume":"19","author":"Saraji","year":"2024","journal-title":"PLoS One"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:34:36Z","timestamp":1778898876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2588931125001257"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}